BioNTech SE (NASDAQ:BNTX) has agreed to acquire Neon Therapeutics (NASDAQ:NTGN) in an all-stock transaction valued at ~$67M ($2.18/share). Under the terms of the deal, Neon shareholders will receive 0.063 of a BNTX ADS for each NEON common share held.
Neon’s lead candidate is NEO-PTC-01, a personalized neoantigen-targeted T cell therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.